A novel interaction between extracellular vimentin and fibrinogen in fibrin formation. Issue 221 (January 2023)

• Record Type: Journal Article
• Authors: Martinez-Vargas, Marina; Cebula, Adrian; Brubaker, Lisa S.; Seshadri, Nitin; Lam, Fong W.; Loor, Michele; Rosengart, Todd K.; Yee, Andrew; Rumbaut, Rolando E.; Cruz, Miguel A.
• Is Part Of: Thrombosis research. Issue 221(2023)
• Page Start: 97
• Page End: 104
• Publication Date: 2023-01
• Subjects: Vimentin -- Coagulopathy -- Systemic inflammation -- Fibrinogen -- sepsis -- COVID-19; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2022.11.028
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Introduction: Thrombosis is frequently manifested in critically ill patients with systemic inflammation, including sepsis and COVID-19. The coagulopathy in systemic inflammation is often associated with increased levels of fibrinogen and D-dimer. Because elevated levels of vimentin have been detected in sepsis, we sought to investigate the relationship between vimentin and the increased fibrin formation potential observed in these patients. Materials and methods: This hypothesis was examined by using recombinant human vimentin, anti-vimentin antibodies, plasma derived from healthy and critically ill patients, confocal microscopy, co-immunoprecipitation assays, and size exclusion chromatography. Results: The level of vimentin in plasma derived from critically ill subjects with systemic inflammation was on average two-fold higher than that of healthy volunteers. We determined that vimentin directly interacts with fibrinogen and enhances fibrin formation. Anti-vimentin antibody effectively blocked fibrin formation ex vivo and caused changes in the fibrin structure in plasma. Additionally, confocal imaging demonstrated plasma vimentin enmeshed in the fibrin fibrils. Size exclusion chromatography column and co-immunoprecipitation assays demonstrated a direct interaction between extracellular vimentin and fibrinogen in plasma from critically ill patients but not in healthy plasma. Conclusions: The results describe that extracellular vimentin engages fibrinogen in fibrin formation. In addition, the data suggest that elevated levels of an apparent aberrant extracellular vimentin potentiate fibrin clot formation in critically ill patients with systemic inflammation; consistent with the notion that plasma vimentin contributes to the pathogenesis of thrombosis. Highlights: Vimentin binds to fibrin(ogen) and potentiates fibrin formation Anti-vimentin antibody blocks fibrin formation ex vivo in plasma from critically ill patients An aberrant extracellular vimentin is present in plasma from patients presenting systemic inflammation.